Inventor
MENTE SCOT RICHARD
US28 patents
⚠️ This page may combine multiple inventors who share the name “MENTE SCOT RICHARD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PFIZER
23 patentsUS9527831B2Dec 27, 2016
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER13 citations92
US9139561B2Sep 22, 2015
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER8 citations92
US9107923B2Aug 18, 2015
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER11 citations92
US9133190B2Sep 15, 2015
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER8 citations84
US8822494B2Sep 2, 2014
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER12 citations84
US10093655B2Oct 9, 2018
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER3 citations83
US9822097B2Nov 21, 2017
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER6 citations83
US9688698B2Jun 27, 2017
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER4 citations73
US9527843B2Dec 27, 2016
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER3 citations73
US10421744B2Sep 24, 2019
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER2 citations72
US10426135B2Oct 1, 2019
Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
PFIZER2 citations71
US10227346B2Mar 12, 2019
Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof
PFIZER1 citations71
US9670201B2Jun 6, 2017
Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
PFIZER3 citations71
US9617275B2Apr 11, 2017
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER5 citations68
US11964961B2Apr 23, 2024
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER0 citations62
US11014909B2May 25, 2021
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER0 citations62
US9856263B2Jan 2, 2018
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER2 citations62
US10385036B2Aug 20, 2019
Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
PFIZER1 citations61
US10336748B2Jul 2, 2019
Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
PFIZER1 citations61
US10077272B2Sep 18, 2018
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER0 citations52
US9868744B2Jan 16, 2018
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER1 citations52
US10696658B2Jun 30, 2020
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER0 citations51
US10316021B2Jun 11, 2019
Heteroarylphenoxy benzamide kappa opioid ligands
PFIZER0 citations35
NUVALENT INC
5 patentsUS11542278B1Jan 3, 2023
Heteroaromatic macrocyclic ether chemotherapeutic agents
NUVALENT INC4 citations71
US11667649B2Jun 6, 2023
Heteroaromatic macrocyclic ether chemotherapeutic agents
NUVALENT INC3 citations69
US12275742B2Apr 15, 2025
Heteroaromatic macrocyclic ether chemotherapeutic agents
NUVALENT INC0 citations59
US12054498B2Aug 6, 2024
Heteroaromatic macrocyclic ether chemotherapeutic agents
NUVALENT INC0 citations59
US12037346B2Jul 16, 2024
Amino-substituted heteroaryls for treating cancers with EGFR mutations
NUVALENT INC1 citations56